查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951571

2026年全球心血管药物市场报告

Cardiotonic Agents Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，正性肌力药物市场发展迅速，预计将从2025年的31.1亿美元成长到2026年的35亿美元，复合年增长率达12.3%。过去几年的增长可归因于心臟衰竭发病率的上升、重症监护中对正性肌力药物支持的依赖、急性心抟出量改善的替代方案有限、心臟外科手术的扩展以及医院心血管护理的普及。

预计未来几年，心臟正性肌力药物市场将快速成长，到2030年市场规模将达到55.6亿美元，复合年增长率（CAGR）为12.3%。预测期内的成长要素包括全球人口老化、晚期心臟衰竭发病率上升、对速效心臟药物的需求、重症监护基础设施的扩建以及心臟重症监护监测技术的改进。预测期内的主要趋势包括：正性肌力药物在急性心臟衰竭中的持续应用、医院倾向于静脉注射、对配糖体药物在心律失常治疗中的持续需求、正性肌力药物在心臟外科手术中的应用以及心血管联合治疗的逐步普及。

未来几年，心血管疾病盛行率的不断上升预计将推动强心剂市场的成长。心血管疾病（CVD）是指一组影响心臟和血管的疾病，包括冠状动脉疾病、心臟衰竭、心律不整和中风。这种增长主要是由于不健康的饮食习惯，例如高饱和脂肪、反式脂肪、盐和添加糖的摄入，这些因素会导致肥胖、高血压和高胆固醇。强心剂可以提高心肌的效率和收缩力，进而改善血液循环，并缓解各种心血管疾病的相关症状。例如，总部位于瑞士的政府间组织—世界卫生组织（WHO）在2023年9月报告称，心血管疾病导致的死亡人数已达1,790万人。因此，心血管疾病盛行率的不断上升正在推动强心剂市场的扩张。

正性肌力药物市场的主要企业正致力于开发创新产品，例如短效正性肌力药物，旨在改善急性心臟衰竭和心源性休克的心臟功能。短效正性肌力药物可暂时改善心臟收缩能力并增加心抟出量。例如，2023年6月，总部位于英国的製药公司Hikma Pharmaceuticals推出了“多巴酚丁胺注射液（USP）”，规格为250毫克/20毫升管瓶。此註射适用于因心臟衰竭收缩力下降而导致心臟衰竭的成年患者，这种情况通常发生在心臟疾病或心血管手术后。多巴酚丁胺透过刺激β1受体发挥作用，可在1至2分钟内迅速起效，改善心肌收缩力和心抟出量。注射液通常在医院环境中以静脉注射给药，并接受严密监测。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球心血管药物市场：吸引力评分与分析
  • 成长潜力分析、竞争评估、策略契合度评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 主要原料、资源和供应商清单
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章 全球市场趋势与策略

  • 关键技术和未来趋势
    • 生物技术、基因组学和精准医学
    • 工业4.0和智慧製造
    • 数位化、云端运算、巨量资料、网路安全
    • 人工智慧（AI）和自主人工智慧
    • 永续性、气候技术和循环经济
  • 主要趋势
    • 急性心臟衰竭持续使用正性肌力药物
    • 医院静脉注射趋势
    • 治疗心律不整对配糖体的需求持续存在
    • 在心臟外科治疗中整合正性肌力药物
    • 逐步过渡到复杂的心血管治疗

第五章 终端用户产业市场分析

  • 医院
  • 心臟监护病房
  • 专科心臟诊所
  • 急诊中心
  • 手术中心

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及新冠疫情对市场的影响

第七章 全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球心血管药物市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球心血管药物市场规模、对比及成长率分析
  • 全球心血管药物市场表现：规模与成长，2020-2025年
  • 全球心血管药物市场预测：规模与成长，2025-2030年，2035年预测

第八章 全球潜在市场规模（TAM）

第九章 市场细分

  • 依药物类型
  • 洋地黄配糖体、磷酸二酯酶抑制剂、心臟保护剂、拟交感神经药和其他药物类型
  • 透过行政途径
  • 口服、静脉注射及其他给药途径
  • 按剂型
  • 片剂、溶液和其他剂型
  • 透过使用
  • 心臟手术、心房颤动、心臟衰竭、肺动脉高压及其他适应症
  • 透过分销管道
  • 医院药局、零售药局、网路药局
  • 依类型细分：洋地黄配糖体
  • 地高辛、洋地黄毒苷、毛花苷 C
  • 按类型细分：磷酸二酯酶抑制剂
  • 米力农、依诺昔酮、氨力农
  • 按类型细分：心臟保护剂
  • Coenzyme Q10、地塞米松、曲美他嗪
  • 依类型细分：拟交感神经药
  • 多巴酚丁胺、多巴胺、正肾上腺素
  • 按类型细分：其他药物类型
  • 左西孟旦、奥美卡比、Cilostazol

第十章 区域与国家分析

  • 全球心血管药物市场：依地区、绩效及预测划分，2020-2025年、2025-2030年预测、2035年预测
  • 全球心血管药物市场：按国家划分，实际结果和预测，2020-2025年、2025-2030年预测、2035年预测

第十一章 亚太市场

第十二章：中国市场

第十三章 印度市场

第十四章 日本市场

第十五章：澳洲市场

第十六章 印尼市场

第十七章 韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第二十章：西欧市场

第21章英国市场

第22章 德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章 东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第30章：加拿大市场

第31章 南美洲市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第35章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 心血管药物市场：竞争格局及市场占有率（2024年）
  • 心血管药物市场：公司估值矩阵
  • 心血管药物市场：公司概况
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • Bayer AG
    • Sanofi SA

第37章：其他领先和创新企业

  • Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.

第38章 全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年心血管药物市场：提供新机会的国家
  • 2030年心血管药物市场：充满新机会的细分市场
  • 2030年心血管药物市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第41章附录

简介目录
Product Code: PH4MCAGE02_G26Q1

Cardiotonic agents are drugs that enhance the efficiency and contraction of the heart muscle, improving its ability to pump blood. They are used to treat heart failure and certain arrhythmias by increasing cardiac output and supporting circulation.

The main types of cardiotonic agents include digitalis glycosides, phosphodiesterase inhibitors, cardioprotectants, sympathomimetic agents, and others. Digitalis glycosides are compounds derived from the Digitalis plant that increase the force of heart contractions and help regulate heart rhythm. These drugs can be administered orally, intravenously, or through other routes, with dosage forms including tablets, solutions, and more. They are applied in various medical situations, such as cardiac surgeries, atrial fibrillation, heart failure, and pulmonary hypertension, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have affected the cardiotonic agents market by increasing the cost of imported APIs and injectable formulations used in hospital-based cardiovascular care. These impacts are most evident in intravenous cardiotonic drugs, particularly in North America and Europe where global API sourcing is common. Asia-Pacific manufacturers have faced supply chain volatility and pricing pressure due to trade barriers. However, tariffs have supported localized manufacturing of essential cardiac injectables, strengthening domestic supply chains.

The cardiotonic agents market research report is one of a series of new reports from The Business Research Company that provides cardiotonic agents market statistics, including cardiotonic agents industry global market size, regional shares, competitors with a cardiotonic agents market share, detailed cardiotonic agents market segments, market trends and opportunities, and any further data you may need to thrive in the cardiotonic agents industry. This cardiotonic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiotonic agents market size has grown rapidly in recent years. It will grow from $3.11 billion in 2025 to $3.5 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to rising incidence of heart failure, reliance on inotropic support in critical care, limited alternatives for acute cardiac output improvement, expansion of cardiac surgery procedures, hospital-centric cardiovascular treatment.

The cardiotonic agents market size is expected to see rapid growth in the next few years. It will grow to $5.56 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to aging global population, increasing advanced heart failure cases, demand for rapid-acting cardiac drugs, expansion of critical care infrastructure, improved monitoring in cardiac intensive care. Major trends in the forecast period include continued use of cardiotonic drugs in acute heart failure, preference for hospital-based intravenous administration, ongoing demand for digitalis glycosides in arrhythmia, integration of cardiotonic agents in surgical cardiac care, gradual shift toward combination cardiovascular therapy.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the cardiotonic agents market in the coming years. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, arrhythmias, and stroke. This rise is largely attributed to unhealthy diets high in saturated fats, trans fats, salt, and added sugars, which contribute to obesity, high blood pressure, and elevated cholesterol levels. Cardiotonic agents enhance the efficiency and contraction strength of the heart muscle, supporting better blood circulation and alleviating symptoms associated with various cardiovascular conditions. For example, in September 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported 17.9 million deaths from cardiovascular diseases. Consequently, the growing prevalence of cardiovascular diseases is fueling the expansion of the cardiotonic agents market.

Leading companies in the cardiotonic agents market are focusing on developing innovative products, such as short-term inotropic drugs, to enhance cardiac performance in acute heart failure and cardiogenic shock. Short-term inotropic drugs temporarily improve the heart's ability to contract, thereby increasing cardiac output. For example, in June 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Dobutamine Injection, USP, in a 250 mg/20 mL vial. This injection is intended for short-term inotropic support in adults experiencing cardiac decompensation due to reduced heart contractility, commonly resulting from heart disease or following cardiac surgery. Dobutamine works by stimulating beta-1 receptors, enhancing heart muscle contractility and cardiac output with a rapid onset of 1-2 minutes. The injection is administered intravenously, typically in a hospital setting under close monitoring.

In April 2023, SK Capital Partners LP, a US-based capital markets firm, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed amount. Through this acquisition, SK Capital aims to accelerate Apotex's growth and innovation by leveraging its expertise to expand global access to affordable, high-quality pharmaceuticals. Apotex Pharmaceutical Holdings Inc., based in Canada, manufactures a cardiotonic agent under the brand name Apo-Digoxin.

Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.

North America was the largest region in the cardiotonic agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cardiotonic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiotonic agents market consists of sales of digoxin, milrinone, dobutamine, levosimendan, and amrinone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiotonic Agents Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cardiotonic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiotonic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiotonic agents market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Drug Type: Digitalis Glycosides; Phosphodiesterase Inhibitors; Cardioprotectants; Sympathomimetic Agents; Other Drug Types
  • 2) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
  • 3) By Dosage Form: Tablet; Solution; Other Dosage Forms
  • 4) By Application: Cardiac Surgical Procedures; Atrial Fibrillation; Heart Failure; Pulmonary Hypertension; Other Applications
  • 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By Digitalis Glycoside: Digoxin; Digitoxin; Lanatoside C
  • 2) By Phosphodiesterase Inhibitors: Milrinone; Enoximone; Amrinone
  • 3) By Cardioprotectants: Coenzyme Q10; Dexrazoxane; Trimetazidine
  • 4) By Sympathomimetic Agents: Dobutamine; Dopamine; Norepinephrine
  • 5) By Other Drug Types: Levosimendan; Omecamtiv Mecarbil; Cilostazol
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG; Eli Lilly and Company; Fresenius Kabi; Aurobindo Pharma Limited; Hikma Pharmaceuticals PLC; Alchem International Private Ltd; Farbe Firma Private Limited; Salius Pharma Pvt. Ltd.; Johnlee Pharmaceuticals Pvt. Ltd.; Healthy Life Pharma Pvt Ltd; Anwita Drugs; Varion Lifesciences; Deccan Nutraceuticals Pvt. Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Cardiotonic Agents Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Cardiotonic Agents Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Cardiotonic Agents Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Cardiotonic Agents Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Industry 4.0 & Intelligent Manufacturing
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Continued Use Of Cardiotonic Drugs In Acute Heart Failure
    • 4.2.2 Preference For Hospital-Based Intravenous Administration
    • 4.2.3 Ongoing Demand For Digitalis Glycosides In Arrhythmia
    • 4.2.4 Integration Of Cardiotonic Agents In Surgical Cardiac Care
    • 4.2.5 Gradual Shift Toward Combination Cardiovascular Therapy

5. Cardiotonic Agents Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Cardiac Care Units
  • 5.3 Specialty Cardiology Clinics
  • 5.4 Emergency Care Centers
  • 5.5 Surgical Centers

6. Cardiotonic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Cardiotonic Agents Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Cardiotonic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Cardiotonic Agents Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Cardiotonic Agents Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Cardiotonic Agents Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Cardiotonic Agents Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Cardiotonic Agents Market Segmentation

  • 9.1. Global Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types
  • 9.2. Global Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oral, Intravenous, Other Route Of Administrations
  • 9.3. Global Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Tablet, Solution, Other Dosage Forms
  • 9.4. Global Cardiotonic Agents Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications
  • 9.5. Global Cardiotonic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
  • 9.6. Global Cardiotonic Agents Market, Sub-Segmentation Of Digitalis Glycoside, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Digoxin, Digitoxin, Lanatoside C
  • 9.7. Global Cardiotonic Agents Market, Sub-Segmentation Of Phosphodiesterase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Milrinone, Enoximone, Amrinone
  • 9.8. Global Cardiotonic Agents Market, Sub-Segmentation Of Cardioprotectants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Coenzyme Q10, Dexrazoxane, Trimetazidine
  • 9.9. Global Cardiotonic Agents Market, Sub-Segmentation Of Sympathomimetic Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Dobutamine, Dopamine, Norepinephrine
  • 9.10. Global Cardiotonic Agents Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Levosimendan, Omecamtiv Mecarbil, Cilostazol

10. Cardiotonic Agents Market Regional And Country Analysis

  • 10.1. Global Cardiotonic Agents Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Cardiotonic Agents Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Cardiotonic Agents Market

  • 11.1. Asia-Pacific Cardiotonic Agents Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Cardiotonic Agents Market

  • 12.1. China Cardiotonic Agents Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Cardiotonic Agents Market

  • 13.1. India Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Cardiotonic Agents Market

  • 14.1. Japan Cardiotonic Agents Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Cardiotonic Agents Market

  • 15.1. Australia Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Cardiotonic Agents Market

  • 16.1. Indonesia Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Cardiotonic Agents Market

  • 17.1. South Korea Cardiotonic Agents Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Cardiotonic Agents Market

  • 18.1. Taiwan Cardiotonic Agents Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Cardiotonic Agents Market

  • 19.1. South East Asia Cardiotonic Agents Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Cardiotonic Agents Market

  • 20.1. Western Europe Cardiotonic Agents Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Cardiotonic Agents Market

  • 21.1. UK Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Cardiotonic Agents Market

  • 22.1. Germany Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Cardiotonic Agents Market

  • 23.1. France Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Cardiotonic Agents Market

  • 24.1. Italy Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Cardiotonic Agents Market

  • 25.1. Spain Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Cardiotonic Agents Market

  • 26.1. Eastern Europe Cardiotonic Agents Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Cardiotonic Agents Market

  • 27.1. Russia Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Cardiotonic Agents Market

  • 28.1. North America Cardiotonic Agents Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Cardiotonic Agents Market

  • 29.1. USA Cardiotonic Agents Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Cardiotonic Agents Market

  • 30.1. Canada Cardiotonic Agents Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Cardiotonic Agents Market

  • 31.1. South America Cardiotonic Agents Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Cardiotonic Agents Market

  • 32.1. Brazil Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Cardiotonic Agents Market

  • 33.1. Middle East Cardiotonic Agents Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Cardiotonic Agents Market

  • 34.1. Africa Cardiotonic Agents Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Cardiotonic Agents Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Cardiotonic Agents Market Regulatory and Investment Landscape

36. Cardiotonic Agents Market Competitive Landscape And Company Profiles

  • 36.1. Cardiotonic Agents Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Cardiotonic Agents Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Cardiotonic Agents Market Company Profiles
    • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

37. Cardiotonic Agents Market Other Major And Innovative Companies

  • Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.

38. Global Cardiotonic Agents Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Cardiotonic Agents Market

40. Cardiotonic Agents Market High Potential Countries, Segments and Strategies

  • 40.1 Cardiotonic Agents Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Cardiotonic Agents Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Cardiotonic Agents Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer